Linked Life Data

3878557

Source:http://linkedlifedata.com/resource/pubmed/id/3878557

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1986-2-5
pubmed:abstractText
A neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which produces pathological changes similar to human idiopathic Parkinson's disease in animals, was injected in mice for biochemical and pharmacological studies. The dopamine concentration showed a marked decrease (-75%) in the striatum 1-2 weeks after the injection of MPTP (30 mg/kg i.p. twice a day for 5 days; a total dose, 300 mg/kg) but no changes or only slight decreases in other brain regions. The norepinephrine concentration also decreased to half the preadministration level in the striatum. These changes closely resembled those observed in the brain of parkinsonian patients. An examination for evaluating bradykinesia of MPTP-treated mice (pole test) devised by the author revealed that bradykinesia was alleviated dose-dependently by injection of L-DOPA. These results suggested that MPTP-treated mice are a useful experimental model for the study of parkinsonism, and that the pole test using these animals is of value in the screening of anti-parkinsonian agents.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0034-5164
pubmed:author
pubmed:issnType
Print
pubmed:volume
50
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
435-41
pubmed:dateRevised
2003-11-14
pubmed:meshHeading
pubmed:year
1985
pubmed:articleTitle
A simple quantitative bradykinesia test in MPTP-treated mice.
pubmed:publicationType
Journal Article